We make healthy cells invisible to targeted therapies
Targeted therapies work by attacking cells that express particular proteins on their surface. Unfortunately, both diseased and healthy cells often express the same proteins, resulting in collateral damage to healthy cells.
At Vor, we engineer hematopoietic stem cells (HSCs) to lack a biologically redundant target protein, then transplant these cells into the patient.
These eHSCs give rise to generations of new healthy blood cells that are effectively invisible to targeted therapies. Diseased cells still display the target protein and are therefore vulnerable to attack. This process potentially broadens the therapeutic window and improves the utility of complementary targeted therapies.
Vor Biopharma is thrilled to have been chosen as the 2019 Xconomy Cell Therapy Platform of the year. We are well-funded by 5AM Ventures and RA Capital, among others. Please visit our website at https://www.vorbiopharma.com/
for more information.
What we value in our fellow Voracians
Enthusiastically driving our science toward innovative medicines
Fostering genuine bonds of collaboration and mentorship
Acting selflessly by putting the collective mission first
As an equal opportunity employer, we at Vor Biopharma know that diversity inspires innovation, inclusiveness, and creativity. We invite you to come as you are. All applicants will be considered for employment agnostic to race, age, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
Who we are looking for
The successful candidate will contribute to advancing Vor’s engineered hematopoietic stem cell products. This will involve working within a team environment to execute experimental plans requiring skills in fundamental cellular biology, cellular engineering, and hematopoietic stem cell biology.
Key areas of responsibility: